Rusk Rehabilitation Brooklyn at 60th Street | NYU Langone Health
NYU Langone’s Rusk Rehabilitation Brooklyn at 60th Street provides rehabilitation therapy to people recovering from illness or injury.
Rusk Rehabilitation Brooklyn at Seventh Avenue Family Health Center | NYU Langone Health
NYU Langone's Rusk Rehabilitation Brooklyn at Seventh Avenue Family Health Center provides therapy for adults and children seven days a week.
Rusk Rehabilitation Brooklyn at Shore Road | NYU Langone Health
NYU Langone’s Rusk Rehabilitation Brooklyn at Shore Road provides rehabilitation care for adults and children in Bay Ridge, Brooklyn.
Rusk Rehabilitation Brooklyn at Sunset Park Family Health Center | NYU Langone Health
Rusk Rehabilitation Brooklyn at Sunset Park Family Health Center provides rehabilitative therapies to adults and children.
Rusk Rehabilitation Brooklyn at Sunset Terrace Family Health Center | NYU Langone Health
NYU Langone’s Rusk Rehabilitation Brooklyn at Sunset Terrace Family Health Center provides rehabilitation therapy to adults recovering from illness or injury.
Rusk Rehabilitation Doctors | NYU Langone Health
Find a doctor at the Rusk Rehabilitation at NYU Langone.
Rusk Rehabilitation Wellness Services | NYU Langone Health
The team at NYU Langone’s Rusk Rehabilitation offers wellness services such as acupuncture and massage to complement your treatment.
S2206 Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
This is a randomized Phase III trial. Eligible participants either are known to have ultrahigh risk (MP2) status using MammaPrint or will undergo screening to determine eligibility. Patients will be initially enrolled in Step 1 to determine eligibility. Participants who do not have MP2 at that time will not be followed further. Participants with MP2 status who consent to be randomized will be enrolled in this parallel randomization open-label design with equal allocation to the two treatment groups: (1) neoadjuvant chemotherapy and (2) neoadjuvant chemotherapy concurrent with durvalumab.
S2212 SHORTER ANTHRACYCLINE-FREE CHEMO IMMUNOTHERAPY ADAPTED TO PATHOLOGICAL RESPONSE IN EARLY TRIPLE NEGATIVE BREAST CANCER (SCARLET) A RANDOMIZED PHASE III STUDY
This is a randomized Phase III trial comparing a standard neoadjuvant chemotherapyregimen to an experimental neoadjuvant chemotherapy regimen that omits AC therapy. Both arms receive pembrolizumab for one year. If participants in the experimental arm have residual disease after neoadjuvant therapy, then they may receive adjuvant therapy post-surgery at physician discretion. This is a parallel randomization open-label design with equal allocation to the two treatment groups: (1) standard neoadjuvant chemotherapy and (2) neoadjuvant chemotherapy without AC. Randomization will be stratified by nodal status (negative or positive).
Safety and Efficacy of the Alleviant System for No-Implant Interatrial Shunt Creation in Patients with Chronic Heart Failure (ALLAY-HF)
ALLAY-HF is a prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF. Patients will be randomized in a 1:1 ratio to undergo the investigational device procedure or a sham-control procedure. The primary analysis will be performed after all study subjects have the opportunity to complete 12 months of follow-up. Regular follow-up visits are planned to occur through 5 years after the index procedure for all study subjects. Sham-control subjects will be offered an opportunity to cross-over after the 24-month follow-up and undergo the investigational device procedure if they meet study eligibility criteria at that time.